• N-MYC/eIF4G1 Survival Axis in inv(16) AML

  2026-09-10

  Peramangalam et al. identify N-MYC and its target eIF4G1 as a previously unrecognized survival axis in inv(16) acute myeloid leukemia. By integrating transcriptional, enhancer, cellular, primary-sample, and patient-derived xenograft analyses, the study connects CBFβ-SMMHC activity with a leukemic gene-expression program that may be therapeutically exploitable.

• AI-10-49 Workflow for inv(16) AML Research

  2026-09-10

  AI-10-49 enables mechanism-led acute myeloid leukemia research by disrupting the CBFβ-SMMHC–RUNX1 interaction and restoring RUNX1-associated transcriptional readouts. This workflow connects target engagement, chromatin immunoprecipitation, MYCN/eIF4G1 pathway analysis, cell survival assays, and carefully controlled in vivo validation.

• Cistanche Nanovesicles Protect Sertoli Cells

  2026-09-09

  A 2025 preprint reports that Cistanche deserticola-derived exosome-like nanovesicles alleviate cyclophosphamide-induced testicular injury by targeting Sertoli-cell cycle arrest. The proposed mechanism links heparan sulfate proteoglycan-mediated uptake with delivery of miR159b-3p, suppression of P21, and phosphorylation-dependent CDK1 activation, while human single-cell data provide translational context.

• Sulfamonomethoxine (SMM): Applied Lab Workflows

  2026-09-09

  Build reproducible SMM assays for DHPS-linked antibacterial studies, veterinary formulation research, and environmental transformation testing. This guide prioritizes solvent control, matrix-matched comparisons, and PK-informed interpretation without transferring unrelated drug parameters.

• Clozapine: Reliable Cell Assay Workflows

  2026-09-08

  This scenario-driven guide explains how Clozapine (SKU B2235) can support reproducible cell viability, proliferation, cytotoxicity, and schizophrenia research workflows. It covers solvent handling, concentration selection, hepatotoxicity study design, ERK1/2 interpretation, and practical supplier evaluation.

• Oteseconazole: A DDI-Aware Assay Framework

  2026-09-08

  Oteseconazole and VT-1161 are examined through a DDI-aware framework that connects fungal CYP51 potency with transporter and human-enzyme assay interpretation. This article provides practical guidance for Candida research, resistant-strain testing, and translational decisions without confusing in vitro activity with clinical conclusions.

• Fzd5 Links Cholesterol to Wnt Signaling in PDAC

  2026-09-07

  The reference study identifies Frizzled5 as a cholesterol-sensing Wnt receptor that connects lipid metabolism with receptor palmitoylation, membrane trafficking, and β-catenin signaling in pancreatic ductal adenocarcinoma. Its findings position cholesterol competition at Fzd5 as a mechanistically grounded strategy for studying Wnt-dependent tumor growth, while also defining important limits for translation beyond the tested cancer context.

• SP600125: Practical JNK Inhibitor Workflows

  2026-09-07

  SP600125 combines nanomolar biochemical activity against JNK1/2/3 with a reversible workflow for studying c-Jun phosphorylation, cytokine expression modulation, apoptosis, and inflammation. This guide emphasizes the critical gap between enzyme potency and cellular response, then converts that insight into practical dosing, controls, troubleshooting, and assay-design choices.

• Magnetic In Vivo CAR-T-Mimicking Cells for Solid Tumors

  2026-09-05

  The reference study introduces a magnetic bispecific nano-antibody that engages endogenous T cells in vivo and guides them toward PDL1-positive solid tumors. Its significance lies in combining local immune-cell reprogramming with externally controlled trafficking, offering a non-genetic alternative to some conventional CAR-T manufacturing and delivery challenges.

• CDELNs and Sertoli Cell Cycle Rescue in Testicular Injury

  2026-09-04

  This reference study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its mechanistic contribution is the linkage of Sertoli-cell uptake through heparan sulfate proteoglycans with delivery of miR159b-3p, suppression of P21, and recovery of CDK1-associated cell-cycle activity.

• Nadolol (SQ-11725) PK Workflow Guide

  2026-09-04

  Nadolol (SQ-11725) supports reproducible beta-adrenergic blockade studies while also enabling transporter-aware pharmacokinetic experiments. This guide connects cardiovascular assay design with disease-state PK insights, offering practical workflows for hypertension research, angina pectoris studies, and vascular headache research.

• Ivermectin Workflows for Parasitology Research

  2026-09-03

  Build more reliable ivermectin assays by combining solvent-aware formulation, dose-response design, motility and viability readouts, and host-cell selectivity controls. The workflow also explains how a pancreatic cancer study can sharpen assay logic without implying that ivermectin has been validated as a Gasdermin C therapy.

• RNA Pol II Inhibition Activates Apoptosis

  2026-09-03

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic program triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcription. The study defines the Pol II degradation-dependent apoptotic response, or PDAR, and provides a framework for interpreting the lethality of transcription-targeting drugs.

• RNA Pol II Loss and Transcription-Independent Cell Death

  2026-09-02

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than simply through depletion of transcripts and proteins. The study defines the Pol II degradation-dependent apoptotic response (PDAR), providing a framework for interpreting transcription-targeting drugs and designing mechanistically resolved cell-death assays.

• AMD-070 Hydrochloride in CXCR4 Research

  2026-09-02

  Build reproducible migration, signaling, Waldenström macroglobulinemia, and anti-HIV research workflows around a soluble CXCR4 antagonist. AMD-070 hydrochloride supports reversible pathway inhibition, genotype-aware assay design, and controlled HIV entry inhibition experiments without committing to a single disease model.

8434 records 1/563 page Next 12345 下5页 Last page